Opinion|Videos|February 27, 2025
Treatment Selection and the Use of Combination Therapies in mCRPC
Panelists discuss how radiopharmaceuticals like lutetium-177 prostate-specific membrane antigen (PSMA) may be preferred over systemic therapy in patients with prostate cancer who have high PSMA expression, multiple bone metastases, and limited visceral disease, particularly after progression on standard therapies like androgen receptor pathway inhibitors and taxane-based chemotherapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In which scenarios would you be more likely to opt for radiopharmaceuticals for prostate cancer treatment vs systemic therapy?
Advertisement
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
4
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
5